ArticleMolecular pharmacology2026
Loss of α-cell GRK2 modulates glucagon response and supports cardiac function.
Article in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pancreatic α-cells secrete glucagon to maintain glucose homeostasis, yet the molecular mechanisms regulating hormone release are understudied. G-protein coupled receptor kinases (GRKs) regulate receptor desensitization; however, their role in α-cells remains unknown. Here, we generated an inducible α-cell-specific GRK2 knockout (αGRK2KO) mouse model to investigate the role of GRK2 in islet physiology, systemic metabolism, and cardiac function. Loss of GRK2 in α-cells reduced islet GRK2 protein by ∼20%, consistent with α-cell islet abundance, and produced negligible alterations in glucose tolerance without affecting insulin secretion. Notably, αGRK2KO mice had altered fast/fed glucagon responses, reduced adiposity, and lower body weight. Despite minimal effects on systemic glucose handling, αGRK2KO animals exhibited improved cardiac function, characterized by enhanced ejection fraction and fractional shortening, without signs of hypertrophy. High-fat, high-sucrose diet feeding abated these changes, underscoring the diet-dependent impact of α-cell GRK2. Together, these findings identify GRK2 as a previously unrecognized regulator of α-cell glucagon secretion that influences systemic energy balance and cardiac performance through endocrine crosstalk. This work establishes a framework for α-cell G protein-coupled receptor regulation and highlights GRK2 as a potential therapeutic node linking islet function, metabolism, and the heart. SIGNIFICANCE STATEMENT: This study explores the role of GRK2 in α-cell biology as a regulator of glucagon dynamics and cardiac function, thereby establishing a new endocrine link between islet signaling and cardiac biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.